HBC September 2017 News Bulletin

Monday, October 9, 2017

Looking Ahead...looking ahead

  • looking aheadThe rollout date for the new Oracle Cloud financial system is set for early December.  Two new videos have been posted on the project website, the first one giving an overview of the systems, and the second one indicating the level of impact for each group of employees.  Please take the time (12 minutes) to view these videos.   Updates, town hall presentations, training session schedules, and online documentation will be posted on the project website.  E-mail announcements will also be sent.
  • Please keep in mind that key dates for the implementation of NIH new FORMS-E are as follow:
    • ➢ September 25, 2017: New FORMS-E Application Instructions are now available on the NIH website.
    • ➢ October25, 2017: FORMS-E Application Packages will be available for FOAs with due dates on or after January 25, 2018.
    • ➢ January 25, 2018: First due dates for new FORMS-E Application Packages.

 

KU NIH Center of Biomedical Research Excellence (CoBRE) in Chemical Biology of Infectious Disease calls for Pilot Project applications

The KU NIH CoBRE in Chemical Biology of Infectious Disease (CBID) has issued a call for Pilot Projects.   These projects must fit with the scientific theme of Chemical Biology of Infectious Disease and make use of at least one of the associated core labs at KU.  Potentially, four projects will be funded at up to $90,000 in direct cost.  They will be for a one-year period with possible renewal for a second year.  A Letter of Intent is due January 2, 2018.   For more information, please consult the announcement.

 

HBC Participant awarded a National Institutes of Health (NIH) Director's New Innovator Award (DP2)

Joanna Slusky, assistant professor of molecular biosciences, was recently awarded a NIH Director's New Innovator Award (DP2).  Joanna SluskyThis program’s goal is to support a few exceptionally creative and promising early stage investigators that propose bold and highly innovative new research approaches and is part of the NIH High-Risk, High-Reward Research Program.  We would like to take this opportunity to congratulate Dr. Slusky and wish her the best with her project.   Information about the High Risk, High Reward Research Program that comprises four different types of awards can be obtained on the NIH website.  Funding opportunities for these awards are released every year in the spring, with applications due in the fall.

 

Important NIH changes concerning research that involves human subjects

If you are conducting or are considering applying for support for research that involves human subjects, please take the time to review some important changes being put forth by the NIH.  You can do so by:

  1. Familiarizing yourself with the new PHS Human Subjects and Clinical Trials Information form (part of the new FORMS-E package to be used for grant applications with due dates of January 25 or beyond).  A NIH video gives an overview of these changes.
  2. Answering these four questions about your current or proposed research:
    • Does the study involve human participants?
    • Are the participants prospectively assigned to an intervention?
    • Is the study designed to evaluate the effect of the intervention on the participants?
    • Is the effect that will be evaluated a health-related biomedical or behavioral outcome?

If the answer to all four questions is yes, then NIH considers your research a clinical trial.  This is crucial in determining if your current research complies with the new NIH policies or if you are choosing the appropriate funding opportunity for future research.

  1. Familiarizing yourself with the NIH policy changes concerning clinical trials.


Grant Submission Deadlines

March 5, 2021
NIH standard deadline for Research Grants and Cooperative Agreements (R01 and U01) – renewal, resubmission, revision.

March 11, 2021
DoD Breast Cancer Breakthrough Award Levels 1 & 2 & Era of Hope Scholar Award – Pre-application.

March 12, 2021
DoD Breast Cancer Breakthrough Award Levels 3 & 4  & Innovator Award – Pre-application.

March 16, 2021
NIH standard deadline for Other Research Grants and Cooperative Agreements (R03, R21, R33, R21/R33, R34, R36, UH2, UH3, UH2/UH3) – renewal, resubmission, revision.

Recent Awards

Yoshiaki Azuma, Professor, Department of Molecular Biosciences, was awarded $35,000 by the University of Kansas Medical Center Research Institute for his project entitled “Targeting mitotic function of the PICH (Polo-like kinase interacting checkpoint helicase) for novel therapeutics of TNBC.”

Heng Du, Associate Professor, Department of Pharmacology & Toxicology, transferred a grant from  the University of Dallas, Texas.  It is a BrightFocus Foundation project entitled “Synaptic mitochondrial calcium uniporter deregulation and synaptic injury in Alzheimer's disease.”

Teruna Siahaan, Aya and Takeru Higuchi Distinguished Professor and Associate Chair, Department of Pharmaceutical Chemistry, was awarded $25,000 by the PHRMA Foundation as mentor for Kelly Schwinghamer for the project entitled “Non-Invasive Brain Delivery Clearance  and Efficacy of Therapeutic Antibodies in Mice.”

Liang Xu, Professor, Department of Molecular Biosciences, was awarded $35,000 by the University of Kansas Medical Center Research Institute for his project entitled “Drug the Undruggable Musashi Oncoprotein by Fragment-based Drug Discovery.”

One of 34 U.S. public institutions in the prestigious Association of American Universities
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
—ALA
5th nationwide for service to veterans —"Best for Vets: Colleges," Military Times
KU Today